Amneal Pharmaceuticals (AMRX) announced that the FDA has tentatively approved the company’s abbreviated new drug application for beclomethasone dipropionate HFA inhalation aerosol. The product is the generic equivalent of Qvar inhalation aerosol.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Mycophenolate Pregnancy Registry: Key Insights for Investors
- Amneal Pharma’s CREXONT Study: A Potential Game-Changer for Parkinson’s Treatment?
- Amneal Pharmaceuticals announces U.S. commercial launch of Brekiya injection
- Amneal treatment of known or suspected cyanide poisoning granted orphan status
- Amneal Pharmaceuticals announces submission of BLA to U.S. FDA for XOLAIR